Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01983501
Title A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Oncothyreon Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine + Tucatinib

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.